TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31116012

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Elevated BMI with diabetes diagnosis
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c levels
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Obesity-associated comorbidities
Number of subjects: 129
Study: 31116158

Group type: EXPERIMENTAL
Intervention: SBP at age 40 (mean 128 mmHg, SD 14)
Number of subjects: 2714

Group type: EXPERIMENTAL
Intervention: DBP at age 40 (mean 78 mmHg, SD 10)
Number of subjects: 2714

Group type: EXPERIMENTAL
Intervention: Pulse pressure at age 40 (mean 50 mmHg, SD 9)
Number of subjects: 2714
Study: 31116389

Group type: EXPERIMENTAL
Intervention: Enoxaparin, 40 mg per day
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Real-time enoxaparin dose adjustment
Number of subjects: 116
Study: 31116405

Group type: EXPERIMENTAL
Intervention: Ovarian tissue transplantation (OTT) after prior chemotherapy exposure
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ovarian tissue transplantation (OTT)
Number of subjects: 31
Study: 31116676

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (initiated in 675 patients, 97%); 600 (89%) treated with low-molecular-weight heparin
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Subsegmental pulmonary embolism
Number of subjects: 695
Study: 31116917

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass in adolescents
Number of subjects: 557

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass in adults
Number of subjects: 557
Study: 31117854

Group type: EXPERIMENTAL
Intervention: Perinatal risk factors (including fetal distress during labor)
Number of subjects: 174

Group type: COMPARATOR
Intervention: None of the studied perinatal risk factors
Number of subjects: 174
Study: 31118108

Group type: EXPERIMENTAL
Intervention: Weekly ONC201 at 625 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Weekly ONC201 at 375 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Weekly ONC201 (general)
Number of subjects: 20
Study: 31118146

Group type: EXPERIMENTAL
Intervention: LAMPOON
Number of subjects: 30
Study: 31118244

Group type: EXPERIMENTAL
Intervention: Patients with DM1
Number of subjects: 33
Study: 31118445

Group type: EXPERIMENTAL
Intervention: HbA1c <7.0%
Number of subjects: 5770

Group type: EXPERIMENTAL
Intervention: BP <140/90 mmHg
Number of subjects: 5770

Group type: EXPERIMENTAL
Intervention: LDL-c <2.6 mmol/L
Number of subjects: 5770

Group type: EXPERIMENTAL
Intervention: Combined three therapeutic targets
Number of subjects: 5770

Group type: COMPARATOR
Intervention: Baseline HbA1c ≥7.0%
Number of subjects: 5770

Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 5770

Group type: COMPARATOR
Intervention: Active smokers
Number of subjects: 5770

Group type: COMPARATOR
Intervention: Patients with physical activities
Number of subjects: 5770
Study: 31118571

Group type: EXPERIMENTAL
Intervention: 60-mg dexlansoprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40-mg esomeprazole
Number of subjects: 0
Study: 31118595

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no testosterone treatment)
Number of subjects: 0
Study: 31118759

Group type: EXPERIMENTAL
Intervention: Pregabalin, dosage and duration not specified
Number of subjects: 0
Study: 31118779

Group type: EXPERIMENTAL
Intervention: cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP)
Number of subjects: 0
Study: 31118909

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Social Cognition Training (SocialMind)
Number of subjects: 0
Study: 31119471

Group type: EXPERIMENTAL
Intervention: cfDNA levels in trauma patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: MPO and cfDNA correlation in septic patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: MPO and cfDNA correlation in trauma patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: H3Cit levels in septic vs trauma patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: cfDNA prognostic utility in trauma patients
Number of subjects: 77
Study: 31119491

Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 31119693

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 1041
Study: 31119947

Group type: EXPERIMENTAL
Intervention: Catechol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31120195

Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg coadministered with methadone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Methadone alone
Number of subjects: 14
Study: 31120201

Group type: EXPERIMENTAL
Intervention: ADHD
Number of subjects: 472

Group type: COMPARATOR
Intervention: Comparison youth
Number of subjects: 472
Study: 31120355

Group type: EXPERIMENTAL
Intervention: Palbociclib at 75 mg, 100 mg, or 125 mg on days 1-12 of each 21-day cycle plus intravenous bortezomib 1.0 mg/m²
Number of subjects: 0
Study: 31120585

Group type: EXPERIMENTAL
Intervention: Auto-titration of EPAP during NIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31121167

Group type: EXPERIMENTAL
Intervention: Pi*ZZ carriers
Number of subjects: 554
Study: 31121319

Group type: EXPERIMENTAL
Intervention: rs7903146 SNP
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: SRH (blood glucose≥11mmol/L in at least two samples during the first 3 days)
Number of subjects: 991
Study: 31121428

Group type: EXPERIMENTAL
Intervention: ACLR limb during preparatory and heelstrike phases of gait
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ACLR limb during heelstrike phase
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ACLR limb
Number of subjects: 75
Study: 31122047

Group type: EXPERIMENTAL
Intervention: Manual analysis of home sleep examinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Automatic analysis of home sleep examinations
Number of subjects: 0
Study: 31122213

Group type: EXPERIMENTAL
Intervention: Circulating 25-hydroxyvitamin D levels above 50 nmol/L (sufficient)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Circulating 25-hydroxyvitamin D levels below 50 nmol/L (insufficient)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Neoadjuvant therapy
Number of subjects: 84
Study: 31122221

Group type: EXPERIMENTAL
Intervention: Patients with LBP
Number of subjects: 264

Group type: COMPARATOR
Intervention: Controls without LBP
Number of subjects: 264
Study: 31122256

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 424

Group type: COMPARATOR
Intervention: Non-statin therapy
Number of subjects: 424
Study: 31122296

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) at a once-weekly dose of 0.8 mg/kg, up to a maximum dose of 50 mg/week
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 127
Study: 31122349

Group type: EXPERIMENTAL
Intervention: CoreValve or Evolut R self-expanding transcatheter aortic valve
Number of subjects: 202
Study: 31122966

Group type: EXPERIMENTAL
Intervention: High birth weight (HBW)
Number of subjects: 4981

Group type: COMPARATOR
Intervention: Normal birth weight (NBW)
Number of subjects: 4981
Study: 31122985

Group type: EXPERIMENTAL
Intervention: Emotional Picture Set of Self-Injury (EPSI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neutral Picture Set
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched Healthy Controls
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched Depressive Controls
Number of subjects: 30
Study: 31122988

Group type: EXPERIMENTAL
Intervention: Assessment for osteonecrosis using MRI scans of the lower limbs and physiotherapy assessment at various time points (within 4 weeks of diagnosis, end of delayed intensification, and 1, 2, and 3 years after the start of maintenance therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical and biochemical data collection at each time point
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone mineral density data and vertebral fracture assessment using dual-energy X-ray absorptiometry
Number of subjects: 0
Study: 31123002

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (MV)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Asynchrony index (AI) calculated from ventilator waveforms
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Survival analysis related to AI
Number of subjects: 103
Study: 31124321

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Levetiracetam Monotherapy
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Levetiracetam Polytherapy
Number of subjects: 491

Group type: COMPARATOR
Intervention: EURAP Registry
Number of subjects: 491

Group type: COMPARATOR
Intervention: North American AED Pregnancy Registry
Number of subjects: 491
Study: 31124335

Group type: EXPERIMENTAL
Intervention: Osimertinib treatment
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Osimertinib treatment in T790M-positive tissue (n=45)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Osimertinib treatment in T790M-positive plasma (n=54)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Rebiopsy success rate
Number of subjects: 188
Study: 31124471

Group type: EXPERIMENTAL
Intervention: Game play with treatment as usual
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study: 31124580

Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg, carfilzomib 20/27 mg/m², dexamethasone (SKd)
Number of subjects: 21
Study: 31124989

Group type: EXPERIMENTAL
Intervention: Antireflux surgery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Preoperative state
Number of subjects: 62
Study: 31125298

Group type: EXPERIMENTAL
Intervention: Wingspan Stent system
Number of subjects: 152
Study: 31125423

Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg with food
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pazopanib 800 mg fasted
Number of subjects: 60
Study: 31126235

Group type: EXPERIMENTAL
Intervention: Sputum specimens
Number of subjects: 347

Group type: COMPARATOR
Intervention: Bronchoscopic specimens
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Scanty sputum/bronchoscopy group
Number of subjects: 347
Study: 31126243

Group type: EXPERIMENTAL
Intervention: Higher self-reported self-determination
Number of subjects: 134

Group type: COMPARATOR
Intervention: Lower self-reported self-determination
Number of subjects: 134
Study: 31126257

Group type: EXPERIMENTAL
Intervention: Breast cancer cases (surgically intervened)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (women surgically intervened for breast augmentation or reduction)
Number of subjects: 0
Study: 31126280

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV) with sulfur hexafluoride (SF6) gas tamponade
Number of subjects: 62
Study: 31126287

Group type: EXPERIMENTAL
Intervention: Patient-related delay
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Healthcare-related delay
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Previous users of inhalation therapy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Misdiagnosis of respiratory symptoms
Number of subjects: 204
Study: 31126291

Group type: EXPERIMENTAL
Intervention: BPD group (26 individuals)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Preterm group (23 individuals)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Asthmatics (23 individuals)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Healthy controls (24 individuals)
Number of subjects: 96
Study: 31126332

Group type: EXPERIMENTAL
Intervention: Nintedanib (200 mg/bid) plus letrozole (2.5 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nintedanib and letrozole
Number of subjects: 19
Study: 31126336

Group type: EXPERIMENTAL
Intervention: High perceived social support (highest quartile of MSPSS)
Number of subjects: 674

Group type: COMPARATOR
Intervention: Low perceived social support (below highest quartile of MSPSS)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: High perceived social support among minorities
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: High perceived social support among Whites
Number of subjects: 674
Study: 31126575

Group type: EXPERIMENTAL
Intervention: CAM treatments (Acupuncture, Reflexology, Guided Imagery)
Number of subjects: 1127

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1127
Study: 31126763

Group type: EXPERIMENTAL
Intervention: TEVAR for ascending aortic disease
Number of subjects: 6
Study: 31126765

Group type: EXPERIMENTAL
Intervention: Valiant Navion stent graft system
Number of subjects: 87
Study: 31126836

Group type: EXPERIMENTAL
Intervention: Radiofrequency Venous Ablation
Number of subjects: 0
Study: 31127422

Group type: EXPERIMENTAL
Intervention: Child self-report version of the State-Trait Anxiety Inventory (STAI)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Caregiver proxy version (STAI-P)
Number of subjects: 201
Study: 31127467

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI)
Number of subjects: 910
Study: 31127481

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 0
Study: 31127700

Group type: EXPERIMENTAL
Intervention: Neuropathic pain patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antidepressants and antiepileptics
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 60
Study: 31127720

Group type: EXPERIMENTAL
Intervention: GlycoLeap mobile lifestyle management program
Number of subjects: 100
Study: 31127735

Group type: EXPERIMENTAL
Intervention: Gene therapy for Parkinson's
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accordion Pill
Number of subjects: 0
Study: 31127814

Group type: EXPERIMENTAL
Intervention: 1H-NMR analysis of serum samples
Number of subjects: 143
Study: 31128146

Group type: EXPERIMENTAL
Intervention: Pencil beam scanning proton beam radiation therapy (PBS-PT) with concurrent 5-fluorouracil (5-FU) and mitomycin C (MMC)
Number of subjects: 25
Study: 31128285

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 10034

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 10034

Group type: EXPERIMENTAL
Intervention: Antibiotic exposure
Number of subjects: 10034

Group type: EXPERIMENTAL
Intervention: Age 60-69 years
Number of subjects: 10034

Group type: EXPERIMENTAL
Intervention: Spring season
Number of subjects: 10034

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 10034

Group type: EXPERIMENTAL
Intervention: Cephalosporins (monotherapy)
Number of subjects: 10034

Group type: EXPERIMENTAL
Intervention: Tetracycline (monotherapy)
Number of subjects: 10034

Group type: EXPERIMENTAL
Intervention: Macrolide (monotherapy)
Number of subjects: 10034

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (monotherapy)
Number of subjects: 10034

Group type: EXPERIMENTAL
Intervention: Quinolones plus carbapenems (combination therapy)
Number of subjects: 10034

Group type: EXPERIMENTAL
Intervention: Quinolones (sequential therapy)
Number of subjects: 10034
Study: 31128503

Group type: EXPERIMENTAL
Intervention: NOAC (51.4% of patients)
Number of subjects: 24137

Group type: COMPARATOR
Intervention: VKA (48.6% of patients)
Number of subjects: 24137
Study: 31128521

Group type: EXPERIMENTAL
Intervention: RelevarEM registry
Number of subjects: 0
Study: 31128598

Group type: EXPERIMENTAL
Intervention: Computer-controlled treadmill training
Number of subjects: 13
Study: 31129440

Group type: COMPARATOR
Intervention: Current BLS TOR rule
Number of subjects: 4360

Group type: EXPERIMENTAL
Intervention: New KoCARC TOR rules (combination of asystole and age > 60 years with current TOR rule)
Number of subjects: 4360
Study: 31129514

Group type: EXPERIMENTAL
Intervention: Vaccinated with bi- or quadrivalent HPV vaccine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: First-void urine
Number of subjects: 55
Study: 31129576

Group type: EXPERIMENTAL
Intervention: Focus groups with clinicians during the preintervention period
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Implementation of pain-agitation-delirium guidelines
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Recognition of challenges in sedation management
Number of subjects: 8
Study: 31129582

Group type: EXPERIMENTAL
Intervention: Surgery for breast cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery for gastric cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery for colorectal cancer
Number of subjects: 0
Study: 31130229

Group type: EXPERIMENTAL
Intervention: Decrease in ACPA levels (>10%)
Number of subjects: 840

Group type: COMPARATOR
Intervention: No change in ACPA levels (-10% to +10%)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Increase in ACPA levels (>+10%)
Number of subjects: 840
Study: 31130500

Group type: EXPERIMENTAL
Intervention: Thyroidectomy
Number of subjects: 43
Study: 31131388

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mechanical AVR
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Model-based therapy planning
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 34
Study: 31131846

Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate (DMPA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonhormonal contraception
Number of subjects: 50
Study: 31132092

Group type: EXPERIMENTAL
Intervention: Ultra-processed food intake (measured as percentage of total energy intake)
Number of subjects: 1822

Group type: EXPERIMENTAL
Intervention: Consumption of specific ultra-processed food groups (yogurts and fermented milks, cakes and pastries, nonalcoholic beverages)
Number of subjects: 1822
Study: 31132118

Group type: EXPERIMENTAL
Intervention: Kisspeptin administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid antagonism (naloxone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NKB and dynorphin signaling
Number of subjects: 0
Study: 31133076

Group type: EXPERIMENTAL
Intervention: Closed-loop system (innovative health technology for blood glucose regulation)
Number of subjects: 24
Study: 31133575

Group type: EXPERIMENTAL
Intervention: Thoracic bioimpedance (TB) and inert gas rebreathing (IGR) techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doppler echocardiography
Number of subjects: 0
Study: 31133596

Group type: EXPERIMENTAL
Intervention: Home-based pregnanediol glucuronide (PDG) urine test
Number of subjects: 25
Study: 31133597

Group type: EXPERIMENTAL
Intervention: 1-hour blood pressure measurement (1-BPM)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Office blood pressure monitoring (OBPM)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Home blood pressure monitoring (HBPM)
Number of subjects: 214

Group type: COMPARATOR
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM)
Number of subjects: 214
Study: 31133863

Group type: EXPERIMENTAL
Intervention: Concurrent exercise regimen (resistance exercise + functional exercise)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Leucine-enriched whey protein isolate supplementation
Number of subjects: 46
Study: 31133889

Group type: EXPERIMENTAL
Intervention: High-frequency neuronavigated repetitive transcranial magnetic stimulation (10 Hz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 0
Study: 31133899

Group type: EXPERIMENTAL
Intervention: Internet-based intervention for depression, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 31133946

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MBI)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 71
Study: 31133957

Group type: EXPERIMENTAL
Intervention: Nicotine Bitartrate
Number of subjects: 0
Study: 31134171

Group type: EXPERIMENTAL
Intervention: Propranolol 0.2% Eye Micro-Drops
Number of subjects: 0
Study: 31134474

Group type: EXPERIMENTAL
Intervention: Standardized fluid challenge during cardiac surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31135462

Group type: EXPERIMENTAL
Intervention: Acupuncture (15-minute traditional needle acupuncture sessions)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 42
Study: 31135970

Group type: EXPERIMENTAL
Intervention: ATIR101 (photodepletion strategy)
Number of subjects: 19
Study: 31136561

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Enterography (MRE)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: MRE-VAS for Mucosal Healing (MH)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: MaRIA score
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Imputed ileal SES-CD
Number of subjects: 237
Study: 31136607

Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 20
Study: 31136632

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire (PHQ-9)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Beck-Depression Inventory II (BDI-II)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Anti-depressive therapy
Number of subjects: 1004
Study: 31136925

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC-10 (3 cycles)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Carboplatin AUC-10 (4 cycles)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC-10
Number of subjects: 48
Study: 31138229

Group type: EXPERIMENTAL
Intervention: PD-1 blockade (pembrolizumab) combined with radiation (3 × 8 Gy) and immune/environmental-targeting compounds (vitamin D, lansoprazole, aspirin, cyclophosphamide, curcumin)
Number of subjects: 49
Study: 31138381

Group type: EXPERIMENTAL
Intervention: Upper airway surgery
Number of subjects: 30
Study: 31138499

Group type: EXPERIMENTAL
Intervention: Good fitness
Number of subjects: 469

Group type: COMPARATOR
Intervention: Overweight
Number of subjects: 469
Study: 31138588

Group type: EXPERIMENTAL
Intervention: Pyrotinib 160 mg, 240 mg, 320 mg, or 400 mg once daily plus capecitabine 1,000 mg/m²
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pyrotinib in combination with capecitabine
Number of subjects: 28
Study: 31138673

Group type: EXPERIMENTAL
Intervention: AXOS-enriched diet
Number of subjects: 0
Study: 31138805

Group type: EXPERIMENTAL
Intervention: Delta-24-RGD
Number of subjects: 0